Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03230318 · ClinicalTrials.gov registry record · Phase 2
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
A Phase 2 study, sponsored by Basilea Pharmaceutica.
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
NCT03230318 is a Phase 2 study that has completed, run by Basilea Pharmaceutica. The registered enrollment target is 148 participants.
The verdict
NCT03230318, a Phase 2 study, has completed, sponsored by Basilea Pharmaceutica.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
Study Summary
This Phase II, open-label, single-arm study evaluated the anti-cancer activity of derazantinib in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) who received at least one prior regimen of systemic therapy. Patients received an oral once-daily total dose of 300 mg derazantinib capsules.
Interventions
- DRUG derazantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2017-09-28 |
| Est. Completion | 2022-10-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03230318
The ClinicalTrials.gov registry entry for NCT03230318 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Basilea Pharmaceutica, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which derazantinib is the first listed.
NCT03230318 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03230318 about?
NCT03230318 is a clinical study titled "Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma". This Phase II, open-label, single-arm study evaluated the anti-cancer activity of derazantinib in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) who received at least one prior regimen of systemic therapy. Patients received an oral once-daily total dose of 300 mg derazan...
What is the current status of trial NCT03230318?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2017-09-28. Estimated completion is 2022-10-25.
What interventions are being tested in trial NCT03230318?
The interventions under investigation include: derazantinib (DRUG).
Who is sponsoring clinical trial NCT03230318?
This trial is sponsored by Basilea Pharmaceutica, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.